198 results about "Gene Deletions" patented technology

Provided herein are diagnostic methods for identifying cancers suitable for treatment with an MTA-cooperative PRMT5 inhibitor, such as antibody-based methods and nucleic acid-based methods. The patients carry mutations that adequately sensitize cancer cells to an MTA-cooperative PRMT5 inhibitor, such as complete and certain partial MTAP gene deletions. Also provided are methods of treating the patients selected by such diagnostic methods.

The invention relates to the technical field of viruses, in particular to a construction method and application of an African swine fever virus strain. According to the invention, the three virulence genes MGF110-9L, EP402R and I73R of the African swine fever virus are taken as targets for the first time to construct a virus strain with deletion of the three virulence genes, and the virus strain is found to be capable of effectively reducing the virus toxicity but retaining better immunogenicity, can improve the immunity of an organism to the African swine fever virus, and has a relatively great application prospect.

The invention relates to a dual ERA-LFD kit for visually and rapidly detecting salmonella typhimurium or a single-phase variant thereof, a primer group and application of the dual ERA-LFD kit and the primer group, and aims at solving the problems that an existing detection method is complex in operation, long in time consumption and depends on professional equipment, and primer cross interference, high false positive rate and incapability of distinguishing the single-phase variant caused by the fact that dual ERA primer design is not standard. Screening to obtain a specific primer probe combination aiming at the fljB gene deletion region and the STM4495 gene; a dual ERA-LFD detection system is constructed, and double targets are synchronously amplified under a constant temperature condition; visual interpretation is realized through a double-detection-line color development mode of the transverse flow test strip. The detection specificity can be remarkably improved, and false positive is effectively avoided; the accurate distinguishing between the salmonella typhimurium and the single-phase variants is realized; the detection process is rapid and simple, does not need professional instruments and personnel, and is suitable for on-site rapid screening; the detection cost is obviously reduced and the basic application feasibility is improved.

The invention belongs to the technical field of biology and new medicine, and discloses a method for constructing a myxobacteria expression chassis with genetic stability and application of the myxobacteria expression chassis. Through gene deletion and overexpression analysis, it is verified that the spontaneous mutation rate of a strain can be reduced by deletion of a TLS pathway and overexpression of RecA, and a myxobacteria strain 2K7 with genetic stability is further constructed on the basis. The spontaneous mutation rate of the new strain is reduced by 11.5 times, and the transformation capability of growth plasmids of the strain is obviously improved. According to the research, the genetic stability of the myxobacteria is improved for the first time through a repair way after modification and replication, and the research method and the research result are innovative.

The invention provides a method for increasing the yield of indole-3-acetic acid through a streptomyces scabies SCAB31831 gene, which comprises the following steps: deleting the SCAB31831 gene in streptomyces scabies through a genetic engineering way to obtain an indole-3-acetic acid high-yield engineering strain, and fermenting the strain to produce the indole-3-acetic acid. Wherein the sequence of the SCAB31831 gene is as shown in SEQ ID NO. 1. The invention also provides an application of the method in preparation of an indole-3-acetic acid high-yield microbial preparation, and provides an indole-3-acetic acid high-yield freeze-dried bacterial powder. According to the invention, the SCAB31831 gene negatively related to the biosynthesis of the indole-3-acetic acid is identified, and the gene is deleted in streptomyces scabies, so that the indole-3-acetic acid high-yield strain and freeze-dried bacterial powder based on the strain are obtained, and a technical support is provided for improving the fermentation yield of the indole-3-acetic acid in industrial production.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The invention relates to the technical field of biology, in particular to application of a rice OsGH17 gene in regulation and control of a rice root system. The regulation of the rice root system is to promote the development of the rice root system or inhibit the development of the rice root system. At present, no literature report about application of the rice OsGH17 gene to regulation and control of rice root systems is found. The invention shows that the OsGH17 gene deletion can promote the development of the rice root system, and the OsGH17 gene overexpression can inhibit the development of the rice root system. The regulation characteristic of the OsGH17 gene on the influence of the rice root system is defined, and an important reference is provided for deeply researching the function and action mechanism of the glucoside hydrolase in the plant in the rice.

The invention provides a toxoplasma gondii gene deletion strain with an immune protection effect and application of the toxoplasma gondii gene deletion strain, and belongs to the technical field of veterinary parasitology, veterinary immunology and parasite molecular biology. According to the toxoplasma gondii gene deletion strain, a gamma-glutamyl hydrolase gene is deleted. The invention also provides a method for constructing the insect strain. The method comprises the following steps: constructing a circular plasmid pSAG1-Cas9-U6-sgGGH; constructing a repair template containing upstream and downstream homologous arms of the gamma-glutamyl hydrolase gene and a DHFR resistance gene; co-transfecting the annular plasmid and the repair template to a toxoplasma gondii ME49 strain; performing drug screening on pyrimethamine to obtain positive monoclone; and confirming that the GGH gene is completely knocked out through PCR (Polymerase Chain Reaction) detection, sequencing analysis and immunofluorescence detection. The toxoplasma gondii gene deletion strain can provide a remarkable protection effect on toxoplasma gondii infection and is high in safety.

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and / or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and / or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

The invention discloses an ADO (adenosine dioxygenase) gene deleted zebrafish model as well as a construction method and application thereof. According to the invention, ADOa gene knockout is carried out on a model organism (zebrafish) to successfully construct an ADO gene deleted zebrafish model. Based on the model, the function of the ADO gene in fish taurine metabolism can be researched more deeply, so that a new scientific basis is provided for understanding the ADO function of zebra fish and even other fishes, and meanwhile, the model can be used for drug screening and provides a theoretical basis and technical support for breeding and genetic improvement of aquaculture industry.

The invention provides a genetic engineering strain and a construction method thereof, the strain is a target gene deleted strain obtained by knocking out a target gene in a rod-shaped bacterial strain, and the target gene is one of minC and minD genes or a gene combination thereof. According to the present invention, the minC and / or minD gene deletion strain is obtained by knocking out the minC and / or minD gene in the rod-shaped bacterial strain, such that cell division abnormality can be caused, chromosome-free small cells are generated, and the small cells have characteristics of biological activity, no chromosome DNA, and no growth or division propagation. The small cells can generate smaller body immune response, and meanwhile, the LPS modified by the small cells can generate smaller cytotoxic reaction, so that side effects can be greatly reduced when the small cells are applied to human or animal bodies.

Methods are provided for detecting gene deletions and driver mutations using tumor-specific methylation patterns from cell-free DNA and tissue biopsies. The methods exploit the mutual exclusivity between tumor-specific methylation and homozygous gene deletion, enabling detection through absence of expected methylation signals. Applications include detection of MTAP, PTEN, and RB1 deletions, as well as prediction of EGFR single nucleotide (SNV) and small (up to 50 base pair) insertions and deletions (indel) driver mutations, enabling identification of patients eligible for targeted therapies.

The invention relates to the technical field of biological medicines, and discloses a construction method and expression application of an Hcp gene deleted strain of a rahnella aqua KCL-5 strain for fish. The Hcp 0186 gene deletion strain is constructed by using a homologous recombination method, the comparison between the deletion strain and a wild strain is carried out, and the result shows that the deletion of the Hcp 0186 gene has an influence on the growth speed, the pathogenicity of the Hcp 0186 gene to the zebra fish is obviously reduced, the survival rate of the infected zebra fish is increased from 0% to 52%, and the Hcp 0186 gene deletion strain can be used as a fish attenuated live vaccine. A recombinant prokaryotic expression vector pET32a-Hcp and expression and purification of fusion protein of the recombinant prokaryotic expression vector pET32a-Hcp are further constructed, and Hcp 0186 rabbit polyclonal antibody serum is prepared as a primary antibody and can be applied to localization expression analysis of fish tissues infected by the bacterium and detection of WB and IHC. Results prove that the Hcp 0186 gene deletion of the strain provides an attenuated strain vaccine and clinical diagnosis and detection application of infected fish of the attenuated strain vaccine, and a scientific basis can be provided for revealing a molecular pathogenic mechanism of the strain and development and application of a mutant strain of the strain.

The invention discloses a quadruple real-time fluorescent quantitative PCR (Polymerase Chain Reaction) primer probe combination for detecting African swine fever virus and application. The primer probe combination comprises a first primer probe combination, a second primer probe combination, a third primer probe combination and a fourth first primer probe combination, the primer probe is capable of specifically targeting ASFV p72 gene, CD2v-I gene, CD2v-II gene and I177L gene, and the detection kit developed based on the primer probe combination can rapidly diagnose African swine fever virus and identify CD2v gene I and II type and CD2v and I177L gene deleted strains. The kit has extremely high sensitivity, the lowest detection limit can reach 8 copies / mu L, it is ensured that trace virus DNA can be detected, and missing detection is avoided.

The invention discloses a toxoplasma gondii double-gene deletion attenuated vaccine strain as well as a construction method and application thereof. The toxoplasma gondii double-gene deletion attenuated vaccine strain is constructed by deleting a ku80 gene and a CDC14 gene on the basis of a toxoplasma gondii type II PLK strain, and is named as PLK [delta] TgKu80 [delta] TgCDC14 ([delta] CDC14 for short), and experimental results show that the pathogenicity of the strain is remarkably reduced after the CDC14 gene is knocked out. In order to further explore the immune protection effect on toxoplasma gondii acute infection mice, secondary acute infection is carried out on mice immunized with delta CDC14 strains, and the result shows that compared with non-immunized group mice, no immunized mice die within 30 days, and all non-immunized mice die within 13 days. Therefore, the double-gene deletion attenuated vaccine strain has the potential of being used as a vaccine, and an effective technical means is provided for preventing toxoplasma gondii infection.

The technical problem is to develop a novel armed oncolytic herpes simplex virus (HSV) with G47 delta as a skeleton. Provided is a pharmaceutical composition containing an IL-12 expression-type genetically recombinant herpes simplex virus (HSV) that has a gene encoding a fusion polypeptide in which a 35 kDa light chain (p35) and a 40 kDa heavy chain (p40) of interleukin 12 (IL-12) are linked by two or more elastin motifs, and that has the following characteristics (a) to (c). (a) the ICP6 gene is deleted or inactivated; (b) deletion or inactivation of the gamma34.5 gene; and (c) the alpha 47 gene is deleted or inactivated.

Provided is an AAV vector capable of expressing a human Mef2c gene in the brain. Specifically, provided are an adeno-associated virus vector capable of expressing a full-length MEF2C protein, and the use thereof. The adeno-associated virus vector can significantly ameliorate the social deficit symptoms of mice with Mef2c gene deletion.

This invention discloses the preparation and application of a substituted heteroaryl ketone compound. The structure of the substituted heteroaryl ketone compound is shown in Formula I, wherein the definitions of each substituent are as described in the specification and claims. The compound of this invention has MAT2A enzyme inhibitory activity and, as a MAT2A inhibitor, can be used to prepare drugs for treating or preventing diseases of MAT2A overexpression and diseases of gene deletion encoding methionine phosphorylase.

The invention relates generally to replication defective HSV-1 vectors, and, more particularly, the invention relates to replication defective HSV-1 vectors comprising an alteration (such as a gene deletion) that prevents expression of one or more infected cell polypeptide 4 (ICP4) and infected cell polypeptide 47 (ICP47) proteins, and their use to deliver one or more genes encoding transgenic proteins that stimulate immune destruction of tumors.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The invention relates to the technical field of biological medicines, and particularly relates to a method for researching the influence of silencing or inhibiting a UBE2G1 gene on the growth of abdominal aortic aneurysm by constructing a UBE2G1 gene function deletion mouse model. Results show that silence or inhibition of UBE2G1 gene expression can inhibit growth of abdominal aortic aneurysm, alleviate destruction of elastic fibers of arterial tissues, reduce levels of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in a body and inhibit polarization of macrophage M1. According to the invention, a certain theoretical basis is provided in the aspect of treatment of abdominal aortic aneurysm by means of biotechnology, and the UBE2G1 gene (or protein) can be used as a drug target for treatment of abdominal aortic aneurysm.

The invention relates to a CRISPR-Cas12-Cas3 gene editing system. The CRISPR-Cas12-Cas3 gene editing system comprises Cas12 nuclease, a coding gene of the Cas12 nuclease or an expression vector of the Cas12 nuclease; crRNA, a coding gene thereof or an expression vector thereof; and Cas3 nuclease, and a coding gene or an expression vector thereof. The system is characterized in that Cas12 only cuts a non-target chain to generate a specific single-chain gap, and accurate starting of Cas3 process excision activity is realized through direct compounding with Cas3, so that directional large fragment deletion is induced under the condition that double-chain breakage is not generated. Compared with a traditional I-type CRISPR system depending on a Cascade complex, the system has the advantages that the components are obviously simplified, and the operation is more convenient. Compared with an editor composed of single Cas12, the method can be used for deleting long-fragment genes and other modifications.

This study describes the construction, identification, and application of a pseudorabies virus (PRV) triple-gene deletion vaccine strain (gI / gE / TK). Based on the JS-2012-ΔgI / gE double-gene deletion strain, the TK virulence gene was further deleted using CRISPR technology. Its pathogenicity was evaluated in KM mice and piglets, and its immunoprotective efficacy was verified in piglets. This provides theoretical support for the clinical prevention and control of pseudorabies; establishes experimental models in mice and pigs to study the immunoprotective efficacy of the triple-gene deletion strain; and prepares for the subsequent development and evaluation of vaccines using PRV strains as vectors.

The invention discloses establishment and application of a flavivirus replication-dependent RNA (Ribonucleic Acid) recombination experiment system, and belongs to the technical field of biology. The RNA recombination system comprises two components: a tembusu virus E gene deleted subgenome replicon CQW1-delta E, and a defective virus genome CQW1-delta NS1 or MM1775-delta NS1 with a part of NS1 gene sequence deleted. The two components cannot generate progeny viruses independently, but after the two components are co-transfected, a large number of recombinant progeny viruses can be generated within several days after transfection due to RNA recombination, the recombination efficiency is extremely high, continuous passage is not needed, the construction period is greatly shortened, and the production cost is saved; meanwhile, the generated progeny virus can form plaques on cells, and by means of plaque counting, the method can be applied to quantitative measurement of the RNA recombination efficiency and analysis of key factors influencing the tembusu virus RNA recombination.

The invention discloses a riemerella anatipestifer double-gene deletion attenuated vaccine candidate strain, a construction method and application, the riemerella anatipestifer double-gene deletion attenuated vaccine candidate strain is a riemerella anatipestifer CH-1 strain B739RS01935-B739RS07625 double-gene deletion attenuated vaccine candidate strain, the preservation number is CCTCC NO: M20251080, the preservation date is May 22, 2025, and the preservation number is CCTCC NO: M20251080. The strain is preserved in China Center for Type Culture Collection, and the address of the preservation unit is Wuhan University, Wuhan, China. After ducklings are immunized by the low virulent strain, the low virulent strain has no obvious influence on weight proliferation of the ducklings and has good safety. And after the ducklings are immunized, the challenge protection rate on RACH-1 wild virulent strains reaches 83.3%, and the immune protection effect is good.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to an orf virus ORF114 or ORF117 gene deleted strain as well as a preparation method and application thereof. The orf virus ORF114 gene deleted strain is obtained by deleting ORF114 on the basis of an orf virus wild strain, and the orf virus ORF117 gene deleted strain is obtained by deleting ORF117 on the basis of the orf virus wild strain. According to the preparation method, on the basis of an ORFV-CF15 strain (ORFV 2015 strain), ORF114 and ORF117 genes of the ORFV-CF15 strain are deleted by using a gene recombination combined Cre-LoxP system, and two orf gene deleted strains are constructed and screened, and the orf virus ORF114 or ORF117 gene deleted strains have the characteristics of low toxicity, good proliferation and enhancement of Th1 type immune response, and can be used as orf gene engineering vaccine candidate strains.

The present application relates to a kind of carp herpesvirus II type ORF150 gene deletion strain and its preparation method and application, belong to aquatic animal disease prevention and control technical field.The present application carp herpesvirus II type ORF150 gene deletion strain preservation number is CCTCC NO:V202603, is preserved in China typical culture preservation center, and is named carp herpesvirus 2 type CyHV-2-SS24-Δ150-GFP Cyvirus cyprinidallo2 The virulence of the present application carp herpesvirus II type ORF150 gene deletion strain is significantly weakened, but still retains good immunogenicity, can induce the immune fish body to produce immune protection to carp herpesvirus II type.ORF Therefore, the present application carp herpesvirus II type ORF150 gene deletion strain can be used as live attenuated vaccine to carp herpesvirus II type, prevent koi and its variety in aquaculture from being infected by carp herpesvirus II type and lead to hematopoietic organ necrosis disease.